Simultaneous automated and continuous monitoring of glucose and lactate in cell cultures
![](/46/pdcnewsitem/07/44/51/CITSens_MeMo_System.jpg)
C-CIT Sensors launches its innovative and easy-to-handle single-use wireless bi-parametric metabolic monitoring system.
C-CIT Sensors has released its new sensor product allowing users to monitor glucose and lactate in-situ and over weeks using one single-use sensor.
The measurement of critical process parameters (CPP) such as glucose and lactate is key to the understanding, development and control of bioprocesses of different kinds. Most labs today rely on frequent sampling and off-line analytics in order to follow the dynamics of a cell culture’s growth and metabolic status. These procedures are often manually conducted resulting in error-prone and risky data acquisition and processing. Many of them consume valuable and significant amounts of cell culture volume (and product) over the complete process time and require high upfront investment for instrumentation.
CITSens MeMo is an electrochemical, enzyme-based sensor with the capacity to be used in defined cell culture media and blood.
The continuous online/in-situ measurement of glucose and lactate as offered by CITSens MeMo adds value to cell line, media and process development projects within the cell bioresearch and biopharma community. The sensor system is unique and delivers real-time information on a culture’s growth behaviour and metabolic state at any given time. Data is being generated at a 20-second frequency and continuously sent to a database via wireless communication out of a closed incubator. Using a smartphone, a round-the-clock observation of your cell culture is here. Through straightforward OPC server connectivity, process control based on the online measured kinetics of glucose consumption and/or lactate generation has become reality.
The benefits are evident: Easy and fast learning about a cell culture’s metabolic behaviour under a given condition and straightforward process development at lowest investment and running cost, no risk of contamination, in-time information and automation, better science and engineering.
The single-use sensor comes as a standard product (a reactor probe containing a PG13.5 thread or as a flow cell sensor) or can be custom-manufactured as a cap sensor fitting any of the widely used brands of different cell culture vessels (T-flask, shake flask, roller bottle).
The product will be exhibited at booth 1732 during the BioProcess International Conference & Exhibition in the Hynes Convention Center, from 4-7 September 2018 and is available for beta testing as of 4 September 2018.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance